地奥心血康软胶囊对冠心病介入术后心绞痛及血清脂质过氧化物的影响
|
摘要
目的探讨地奥心血康软胶囊对冠心病介入术后心绞痛及血清脂质过氧化物的影响。方法按随机数字表法将2015年12月—2017年8月行冠状动脉介入术治疗的88例冠心病患者分为观察组和对照组,每组44例。对照组患者接受常规综合治疗,观察组在常规综合治疗基础上使用地奥心血康软胶囊治疗,3次/d,2粒/次。两组均连续治疗3个月。比较两组生命质量[西雅图心绞痛量表(SAQ)评分]、血清脂质过氧化物[超氧化物歧化酶(SOD)、丙二醛(MDA)]、超敏C反应蛋白(hs-CRP)、心绞痛和用药安全性。结果治疗后,两组心绞痛稳定状态、躯体活动受限、治疗满意程度、心绞痛发作情况、疾病认识程度评分均较治疗前明显升高,同组治疗前后比较差异有统计学意义(P<0.05);且观察组心绞痛稳定状态、躯体活动受限、心绞痛发作情况评分和总分均高于对照组,差异具有统计学意义(P<0.05);两组治疗满意程度和疾病认知程度评分比较,差异无统计学意义。治疗后,两组MDA水平均降低,SOD水平均升高,同组治疗前后比较差异有统计学意义(P<0.05);观察组MDA水平低于对照组,SOD水平高于对照组,差异具有统计学意义(P<0.05)。观察组心绞痛治疗有效率为90.91%,高于对照组的72.73%,差异具有统计学意义(P<0.05)。治疗后两组hs-CRP水平均明显降低,同组治疗前后比较差异有统计学意义(P<0.05);且观察组hs-CRP水平低于对照组,差异具有统计学意义(P<0.05)。两组患者治疗期间均未出现明显的不良反应。结论地奥心血康软胶囊能缓解冠心病介入术后心绞痛症状,改善血清脂质过氧化物水平,降低炎性反应,提高患者生命质量。
Objective To investigate the effect of Di'ao Xinxuekang Soft Capsules on postoperative angina pectoris and serum lipid peroxide in coronary heart disease(CHD) patients with percutaneous coronary intervention(PCI). Methods A Total of 88 CHD patients treated with PCI in the hospital from December 2015 to August 2017 were divided into two groups according to random number table, with 44 cases in each group. Control group was given routine comprehensive treatment, while observation group was treated with Di'ao Xinxuekang soft capsules based on control group, with two pills three times a day. And the two groups were treated for three months. The living quality [Seattle angina questionnaire(SAQ)], serum lipid peroxide [superoxide dismutase(SOD), malondialdehyde(MDA)], hypersensitive C-reactive protein(hs-CRP), angina pectoris, safety of medication were compared between the two groups.Results After treatment, the scores of anginal stability, physical limitation, treatment satisfaction, attacks of angina pectoris, illness cognition in the two groups were higher than those before treatment, and there was statistical difference in the same group before and after treatment(P < 0.05); The scores of anginal stability, physical limitation, attacks of angina pectoris and total scores in observation group were higher than those in control group(P < 0.05); There was no statistical difference in the scores of treatment satisfaction and illness cognition between the two groups. After treatment, the MDA levels of the two groups decreased and SOD levels increased, and there was statistical difference in the same group before and after treatment(P < 0.05); The level of MDA in observation group was lower than that in control group, while the level of SOD in observation group was higher than that in control group(P < 0.05). The curative effective rate of angina pectoris in observation group [90.91%(40/44)] was higher than that in control group [72.73%(32/44)](P < 0.05). After treatment, the levels of hs-CRP in the two groups significantly decreased, and there was statistical difference in the same group before and after treatment(P < 0.05). The level of hs-CRP in observation group was lower than that in control group(P < 0.05). There were no obvious adverse reactions in the two groups during treatment. Conclusion Di'ao Xinxuekang Soft Capsules for CHD) patients with PCI can effectively relieve postoperative angina pectoris, improve the level of serum lipid peroxide, decrease the inflammatory response and increase patients' living quality.
Objective To investigate the effect of Di'ao Xinxuekang Soft Capsules on postoperative angina pectoris and serum lipid peroxide in coronary heart disease(CHD) patients with percutaneous coronary intervention(PCI). Methods A Total of 88 CHD patients treated with PCI in the hospital from December 2015 to August 2017 were divided into two groups according to random number table, with 44 cases in each group. Control group was given routine comprehensive treatment, while observation group was treated with Di'ao Xinxuekang soft capsules based on control group, with two pills three times a day. And the two groups were treated for three months. The living quality [Seattle angina questionnaire(SAQ)], serum lipid peroxide [superoxide dismutase(SOD), malondialdehyde(MDA)], hypersensitive C-reactive protein(hs-CRP), angina pectoris, safety of medication were compared between the two groups.Results After treatment, the scores of anginal stability, physical limitation, treatment satisfaction, attacks of angina pectoris, illness cognition in the two groups were higher than those before treatment, and there was statistical difference in the same group before and after treatment(P < 0.05); The scores of anginal stability, physical limitation, attacks of angina pectoris and total scores in observation group were higher than those in control group(P < 0.05); There was no statistical difference in the scores of treatment satisfaction and illness cognition between the two groups. After treatment, the MDA levels of the two groups decreased and SOD levels increased, and there was statistical difference in the same group before and after treatment(P < 0.05); The level of MDA in observation group was lower than that in control group, while the level of SOD in observation group was higher than that in control group(P < 0.05). The curative effective rate of angina pectoris in observation group [90.91%(40/44)] was higher than that in control group [72.73%(32/44)](P < 0.05). After treatment, the levels of hs-CRP in the two groups significantly decreased, and there was statistical difference in the same group before and after treatment(P < 0.05). The level of hs-CRP in observation group was lower than that in control group(P < 0.05). There were no obvious adverse reactions in the two groups during treatment. Conclusion Di'ao Xinxuekang Soft Capsules for CHD) patients with PCI can effectively relieve postoperative angina pectoris, improve the level of serum lipid peroxide, decrease the inflammatory response and increase patients' living quality.
引文
[1] Sun K, Fu C, Nie S, et al. The index and improvement effect of using Danhong injection to patients with atherosclerosis symptoms of coronary heart disease(CHD)[J]. Pak J Pharm Sci, 2014, 27(5 Suppl):1699-1704.
[2]叶达平,王力.血脂康联合依折麦布对老年冠心病病人血脂及hs-CRP的影响[J].中西医结合心脑血管病杂志, 2017, 15(16):2081-2082.
[3]张小平.阿托伐他汀钙片结合氨氯地平治疗高血压合并冠心病患者的临床效果[J].医疗装备, 2017, 30(20):89-90.
[4]张颖丽.地奥心血康软胶囊治疗急性脑梗死疗效观察及对患者血清超氧化物歧化酶和丙二醛水平的影响[J].中国基层医药, 2014, 21(2):272-273.
[5]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.冠心病诊断和治疗指南(2007版)[J].中华心血管病杂志, 2007, 35(3):195-206.
[6] Arnold S V, Kosiborod M, Li Y, et al. Comparison of the Seattle Angina Questionnaire with daily angina diary in the TERISA clinical trial[J]. Circ Cardiovasc Qual Outcomes, 2014, 7(6):844-850.
[7]陈灏珠.实用内科学[M]. 12版.北京:人民卫生出版社, 2014:1467-1471.
[8] Panov A V, Alugishvili M Z, Abesadze I T, et al. The antihypertensive effect of the fixed combination of lisinopril and mmlodipine in patients with coronary heart disease after coronary artery bypass grafting[J].Kardiologiia, 2015, 55(6):27-33.
[9]李力,徐照,吴春叶,等.补气活血方治疗冠心病心绞痛的临床疗效及对炎症反应的干预作用[J].中医药信息, 2017, 34(3):89-92.
[10]张璇,王硕仁,李瑞杰.冠心病经皮冠状动脉介入术后心脏康复的中医药治疗研究进展[J].中西医结合心脑血管病杂志, 2017, 15(4):428-432.
[11]石宏萍,郁一波.自拟益心汤治疗冠心病心绞痛34例[J].中国中医药科技, 2017, 24(3):386-387.
[12]刘建利,张新新,杨洋,等.地奥心血康胶囊中甾体皂苷类成分的HPLC-ELSD指纹图谱[J].中国医药工业杂志, 2015, 46(1):65-67.
[13]林英忠,王虹,金献萍,等.地奥心血康软胶囊对急性ST段抬高型心肌梗死患者循环微RNA-92 a表达的影响[J].广西医学, 2014, 36(11):1538-1541.
[14]马岩敏,邵亚婷.地奥心血康药理性预适应对急性心肌梗死的影响[J].中国临床医生杂志, 2015, 43(12):35-37.
[15]郑海娟,王维亭,郝春华,等.地奥心血康对大鼠心肌缺血再灌注损伤的治疗作用[J].天津医药, 2015, 43(5):491-495.
[2]叶达平,王力.血脂康联合依折麦布对老年冠心病病人血脂及hs-CRP的影响[J].中西医结合心脑血管病杂志, 2017, 15(16):2081-2082.
[3]张小平.阿托伐他汀钙片结合氨氯地平治疗高血压合并冠心病患者的临床效果[J].医疗装备, 2017, 30(20):89-90.
[4]张颖丽.地奥心血康软胶囊治疗急性脑梗死疗效观察及对患者血清超氧化物歧化酶和丙二醛水平的影响[J].中国基层医药, 2014, 21(2):272-273.
[5]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.冠心病诊断和治疗指南(2007版)[J].中华心血管病杂志, 2007, 35(3):195-206.
[6] Arnold S V, Kosiborod M, Li Y, et al. Comparison of the Seattle Angina Questionnaire with daily angina diary in the TERISA clinical trial[J]. Circ Cardiovasc Qual Outcomes, 2014, 7(6):844-850.
[7]陈灏珠.实用内科学[M]. 12版.北京:人民卫生出版社, 2014:1467-1471.
[8] Panov A V, Alugishvili M Z, Abesadze I T, et al. The antihypertensive effect of the fixed combination of lisinopril and mmlodipine in patients with coronary heart disease after coronary artery bypass grafting[J].Kardiologiia, 2015, 55(6):27-33.
[9]李力,徐照,吴春叶,等.补气活血方治疗冠心病心绞痛的临床疗效及对炎症反应的干预作用[J].中医药信息, 2017, 34(3):89-92.
[10]张璇,王硕仁,李瑞杰.冠心病经皮冠状动脉介入术后心脏康复的中医药治疗研究进展[J].中西医结合心脑血管病杂志, 2017, 15(4):428-432.
[11]石宏萍,郁一波.自拟益心汤治疗冠心病心绞痛34例[J].中国中医药科技, 2017, 24(3):386-387.
[12]刘建利,张新新,杨洋,等.地奥心血康胶囊中甾体皂苷类成分的HPLC-ELSD指纹图谱[J].中国医药工业杂志, 2015, 46(1):65-67.
[13]林英忠,王虹,金献萍,等.地奥心血康软胶囊对急性ST段抬高型心肌梗死患者循环微RNA-92 a表达的影响[J].广西医学, 2014, 36(11):1538-1541.
[14]马岩敏,邵亚婷.地奥心血康药理性预适应对急性心肌梗死的影响[J].中国临床医生杂志, 2015, 43(12):35-37.
[15]郑海娟,王维亭,郝春华,等.地奥心血康对大鼠心肌缺血再灌注损伤的治疗作用[J].天津医药, 2015, 43(5):491-495.